Key result
Early protocolized Impella use may improve survival in infarct-related cardiogenic shock despite more complications.
Why the study?
Despite expanding use of axial-flow percutaneous ventricular assist devices for advanced cardiac dysfunction, uncertainties remain regarding optimal timing, patient selection, protocols, and outcomes.
Design
State-of-the-art review
Authors
Loading...
May warrant protocolized early Impella in selected infarct shock despite complications; extends RCT evidence on mechanical support timing.
This state-of-the-art review highlights that while percutaneous microaxial flow pumps may improve survival in selected patients with infarct-related cardiogenic shock, their use is associated with significant complications and requires careful patient selection.
Filippo et al. (2025) conducted a review in Advanced cardiac dysfunction, cardiogenic shock, and high-risk percutaneous coronary intervention. Axial-flow percutaneous ventricular assist devices (Impella) was evaluated. Early and protocolized use of Impella devices may improve survival in selected patients with infarct-related cardiogenic shock, though balanced against higher rates of complications.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: